Cerliponase alfa 24 month review

This review aimed to undertake an assessment after 24 months listing on the LSDP to ensure that the listing of cerliponase alfa for the treatment of CLN2 disease remains appropriate. This review was considered by the Expert Panel at its October 2021 meeting.


Cerliponase alfa 24 month review – Summary

Cerliponase alfa 24 month review – consumer version

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Publication type:
General public

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.